MedTrace Logo

Campath-1H Induction to Allow Steroid Free Immunosuppression in Pediatric Renal Transplantation

NCT00167661 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2020-09-21

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether Campath-1H induction and the associated lymphocyte depletion will permit long-term rejection-free renal allograft survival in the absence of ongoing corticosteroid administration.

Conditions

  • Disorder Related to Renal Transplantation

Interventions

DRUG

Campath-1H

two intravenous 20mg/m2/doses, the first on the day of transplant and the second dose on day 1 post transplant

Sponsors & Collaborators

  • University of Wisconsin, Madison

    lead OTHER

Principal Investigators

  • Sharon M Bartosh, MD · University of Wisconsin, Madison

  • Sharon M Bartosh, MD · University of Wisconsin, Madison

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Months
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-06-30
Primary Completion
2011-12-31
Completion
2012-05-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00167661 on ClinicalTrials.gov